2026-04-29T04:09:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/95922025-06-17T10:29:43Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19616

00925njm 22002777a 4500 dc Cidre-Aranaz, Florencia author Alonso, Javier author 2015 Ewing sarcoma is an aggressive bone malignancy that affect children and young adults. Ewing sarcoma is the second most common primary bone malignancy in pediatric patients. Although significant progress has been made in the treatment of Ewing sarcoma since it was first described in the 1920s, in the last decade survival rates have remained unacceptably invariable, thus pointing to the need for new approaches centered in the molecular basis of the disease. Ewing sarcoma driving mutation, EWS-FLI1, which results from a chromosomal translocation, encodes an aberrant transcription factor. Since its first characterization in 1990s, many molecular targets have been described to be regulated by this chimeric transcription factor. Their contribution to orchestrate Ewing sarcoma phenotype has been reported over the last decades. In this work, we will focus on the description of a selection of EWS/FLI1 targets, their functional role, and their potential clinical relevance. We will also discuss their role in other types of cancer as well as the need for further studies to be performed in order to achieve a broader understanding of their particular contribution to Ewing sarcoma development. Front Oncol. 2015 Jul 20;5:162. 2234-943X http://hdl.handle.net/20.500.12105/9592 26258070 10.3389/fonc.2015.00162 Frontiers in oncology CCK DAX-1 EWS/FLI1 Ewing sarcoma FOXM1 FOXO1 GLI1 LOX EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma